학술논문

Intralipid supplementation in women with recurrent spontaneous abortion and elevated levels of natural killer cells.
Document Type
Journal Article
Source
International Journal of Gynecology & Obstetrics. Dec2016, Vol. 135 Issue 3, p324-327. 4p.
Subject
*MISCARRIAGE
*DIETARY supplements
*INTRACYTOPLASMIC sperm injection
*HUMAN in vitro fertilization
*EMBRYO transfer
*RANDOMIZED controlled trials
*RECURRENT miscarriage
*BIRTH rate
*COMPARATIVE studies
*EMULSIONS
*FERTILIZATION in vitro
*HUMAN reproductive technology
*KILLER cells
*RESEARCH methodology
*EVALUATION of medical care
*MEDICAL cooperation
*PHOSPHOLIPIDS
*PREGNANCY
*FIRST trimester of pregnancy
*RESEARCH
*SOY oil
*EVALUATION research
*BLIND experiment
*THERAPEUTICS
Language
ISSN
0020-7292
Abstract
Objective: To investigate the efficacy of intralipid supplementation in women with recurrent spontaneous abortion (RSA) and elevated natural killer cell activity undergoing in vitro fertilization/intracytoplasmic sperm injection.Methods: Between February 10, 2013, and April 30, 2015, a double-blind randomized controlled study was conducted at a center in Egypt. Women with unexplained secondary infertility, RSA, and elevated levels of natural killer cells (>12%) were enrolled and randomly assigned to receive intralipid (2mL diluted at 20% in 250mL saline) or saline (250mL) infusion on the day of oocyte retrieval using random numbers and sealed envelopes. Patients and attending physicians were masked to group assignment. The infusions were repeated within 1week of a positive pregnancy test and then every 2weeks until the end of the first trimester. The primary outcome was chemical pregnancy 14days after embryo transfer. Analyses were by intention-to-treat.Results: Overall, 296 women were enrolled. Chemical pregnancy was recorded for 84 (58.3%) of 144 women in the intralipid group and 76 (50.0%) of 152 in the control group (P=0.129).Conclusion: Intralipid supplementation did not increase frequency of chemical pregnancy. However, findings related to ongoing pregnancy and live birth should be investigated further. ClinicalTrials.gov:NCT01788540. [ABSTRACT FROM AUTHOR]